Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $115 to $114.
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $115 to $114.